SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Threshold Pharmaceuticals, Inc. Announces Preliminary Data From Phase 1/2 Study of TH-302 in Combination With Bevacizumab in Patients With Recurrent Glioblastoma